Search Result

Results for "

systemic lupus erythematosus

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Apoptosis (6) Autophagy (6) Btk (3) CD19 (1) CD20 (1) Glucocorticoid Receptor (3) IFNAR (1) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (1) NF-κB (2) p38 MAPK (1) Parasite (4) Potassium Channel (3) Protein Arginine Deiminase (1) ROS Kinase (3) SARS-CoV (4) TNF Receptor (5) Toll-like Receptor (TLR) (6)
By Research Areas:	Cancer (13) Endocrinology (4) Infection (4) Inflammation/Immunology (32) Metabolic Disease (3)
Oligonucleotides:	CpG ODNs (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99842A

Dapirolizumab	TNF Receptor	Inflammation/Immunology
Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus .

HY-B0214

Prednisone 5+ Cited Publications Dehydrocortisone	Glucocorticoid Receptor Apoptosis	Inflammation/Immunology Endocrinology Cancer
Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .

HY-P99315

Ruplizumab BG 9588; Anti-Human CD40L Recombinant Antibody	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research .

HY-15374

Frentizole	Amyloid-β	Inflammation/Immunology
Frentizole, an FDA-approved immunosuppressant, is a Aβ-ABAD (binding alcohol dehydrogenase) interaction inhibitor with an IC₅₀ value of 200 μM. Frentizole is used in studies of diseases related to rheumatoid arthritis and systemic lupus erythematosus .

HY-P99219

Sifalimumab MEDI-545; MDX 1103	IFNAR	Inflammation/Immunology
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .

HY-109143B

(R)-Elsubrutinib (R)-ABBV-105	Btk	Inflammation/Immunology Cancer
(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer .

HY-W031727

Hydroxychloroquine Maximum Cited Publications 55 Publications Verification	Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy	Infection Cancer
Hydroxychloroquine (HCQ) is a synthetic oral antimalarial drug that can be used in the study of malaria and autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Hydroxychloroquine is a potent autophagic flux inhibitor with antiviral activity (such as SARS-CoV-2 virus) that inhibits Toll-like receptor 7/9 (TLR7/9) signaling .

HY-B0214S2

Prednisone-d4 Dehydrocortisone-d4	Apoptosis Glucocorticoid Receptor Isotope-Labeled Compounds	Inflammation/Immunology Endocrinology Cancer
Prednisone-d₄ is deuterated labeled Prednisone (HY-B0214). Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .

HY-113986B

(S)-Dexfadrostat (S)-Fadrozole; (S)-CGS 16949A free base; (S)-FAD286	Others	Inflammation/Immunology Endocrinology Cancer
(S)-Dexfadrostat ((S)-Fadrozole) is an aromatase inhibitor with an IC₅₀ of 4.6 nM in human placental microsomes in vitro. (S)-Dexfadrostat can be used in the study of estrogen-dependent breast cancer, gynecomastia, and systemic lupus erythematosus .

HY-136093B

Lixumistat IM156 free base; HL156A free base; HL271 free base	Mitochondrial Metabolism	Cancer
Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat also suppresses B-cell activation to alleviate systemic lupus erythematosus .

HY-153460

TLR7/8/9 antagonist 2	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8/9 antagonist 2 is an orally active TLR7/8/9 antagonist. TLR7/8/9 antagonist 2 has inhibitory activities for HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC₅₀ values of 0.011 μM, 0.029 μM and 0,052 μM, respectively.TLR7/8/9 antagonist 2 has high bioavailability in vivo.TLR7/8/9 antagonist 2 can be used for the research of auto-inflammatory diseases such as systemic lupus erythematosus or lupus nephritis .

HY-P3560

Edratide TV 4710	Apoptosis	Inflammation/Immunology
Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis (Apoptosis) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE) .

HY-148411

Abetimus LJP 394 free base	Others	Inflammation/Immunology
Abetimus (LJP 394 free base) is an immunosuppressant consisting of four double-stranded DNA (dsDNA) oligonucleotides. Abetimus is capable of crosslinking anti-dsDNA antibodies on the surface of B cells, and decreases anti-dsDNA antibodies levels. Abetimus has the potential for research of systemic lupus erythematosus .

HY-P99220

Tabalumab LY2127399	TNF Receptor	Inflammation/Immunology Cancer
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .

HY-162649

TIC10g	Toll-like Receptor (TLR) NF-κB p38 MAPK	Inflammation/Immunology
TIC10g is a dual inhibitor for toll-like receptor 7 and 9 (TLR7 and TLR9), which inhibits TLR7 and TLR9 mediated TNF-α release in mouse macrophages (IC₅₀ is 14.5 μM and 6.5 μM) and human B lymphocytes (IC₅₀ is 7.69 μM and 11.5 μM). TIC10g inhibits the activation of NF-κB and MAPK, and exhibits anti-inflammatory activity against systemic lupus erythematosus and rheumatoid arthritis .

HY-139567

Afimetoran BMS-986256	Toll-like Receptor (TLR) NF-κB Apoptosis	Inflammation/Immunology
Afimetoran (BMS-986256) is an orally active, selective, and highly bioavailable TLR7/8 antagonist. Afimetoran (BMS-986256) can inhibit TLR7/8 activation of the NF-κB pathway and reverse TLR7 mediated resistance to steroid induced apoptosis in plasma cell like dendritic cells (pDCs). Afimetoran (BMS-986256) can be used for research on inflammation and autoimmune diseases (systemic lupus erythematosus) .

HY-P99761

Obexelimab XmAb5871	CD19 Apoptosis	Inflammation/Immunology
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .

HY-105037

Forigerimod IPP-201101	Autophagy	Inflammation/Immunology
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-105037A

Forigerimod TFA IPP-201101 TFA	Autophagy	Inflammation/Immunology
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-P99325

Toralizumab IDEC-131; Anti-Human CD40 ligand Recombinant Antibody	TNF Receptor	Inflammation/Immunology
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .

HY-115676

GSK199 analog hydrochloride	Protein Arginine Deiminase	Inflammation/Immunology
GSK199 analog hydrochloride belongs to a class of compounds that inhibit PAD4 (guanidinoarginine deiminase 4). GSK199 analog hydrochloride has potential uses in diseases including rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis .

HY-B0214R

Prednisone (Standard) Dehydrocortisone (Standard)	Glucocorticoid Receptor Apoptosis	Inflammation/Immunology Endocrinology Cancer
Prednisone (Standard) is the analytical standard of Prednisone. This product is intended for research and analytical applications. Prednisone (Adasone) is a corticosteroid agent with anti-inflammatory and immunosuppressive effects that can be used to study diseases related to systemic lupus erythematosus .

HY-18018

RN486 3 Publications Verification	Btk	Inflammation/Immunology
RN486 is a potent, selective and orally active Btk inhibitor with an IC₅₀ of 4.0 nM and a K_d of 0.31 nM. RN486 is less active for other kinases. RN486 can be used for rheumatoid arthritis and systemic lupus erythematosus research .

HY-150095

YE6144	Others	Inflammation/Immunology
YE6144 is a prototypical interferon regulatory factor 5 (IRF5) inhibitor. YE6144 selectively suppresses IRF5 activity through inhibition of IRF5 phosphorylation .

HY-P9952

Belimumab 2 Publications Verification LymphoStat B	TNF Receptor CD20	Inflammation/Immunology Cancer
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research .

HY-17437A

Mefloquine hydrochloride 3 Publications Verification Mefloquin hydrochloride	Parasite SARS-CoV Autophagy Potassium Channel ROS Kinase	Infection Metabolic Disease Inflammation/Immunology Cancer
Mefloquine hydrochloride (Mefloquin hydrochloride), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine hydrochloride is also a K ⁺ channel (KvQT1/minK) antagonist with an IC₅₀ of ~1 μM. Mefloquine hydrochloride can be used for malaria, systemic lupus erythematosus and cancer research .

HY-150740

ODN 21595	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE) .

HY-150740A

ODN 21595 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 21595 sodium is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 sodium inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 sodium reduces the expression of CD86 and HLA-DR. ODN 21595 sodium has the potential for the research of systemic lupus erythematosus (SLE) .

HY-17437

Mefloquine 3 Publications Verification Mefloquin	Parasite Autophagy SARS-CoV Potassium Channel ROS Kinase	Infection Metabolic Disease Inflammation/Immunology Cancer
Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K ⁺ channel (KvQT1/minK) antagonist with an IC₅₀ of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research .

HY-17437AR

Mefloquine hydrochloride (Standard)	Parasite SARS-CoV Autophagy Potassium Channel ROS Kinase	Infection Metabolic Disease Inflammation/Immunology Cancer
Mefloquine (hydrochloride) (Standard) is the analytical standard of Mefloquine (hydrochloride). This product is intended for research and analytical applications. Mefloquine hydrochloride (Mefloquin hydrochloride), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine hydrochloride is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine hydrochloride can be used for malaria, systemic lupus erythematosus and cancer research .

HY-19834

Fenebrutinib 5+ Cited Publications GDC-0853	Btk	Cancer
Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with K_is of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. Fenebrutinib has the potential for rheumatoid arthritis and systemic lupus erythematosus research .

HY-147642

ChemR23-IN-4	Others	Inflammation/Immunology
ChemR23-IN-4 (Compound 13) is a potent and orally efficacious ChemR23 inhibitor with an IC₅₀ of 17 nM against human ChemR23 .

Cat. No.	Product Name	Target	Research Area

HY-P3560

Edratide TV 4710	Apoptosis	Inflammation/Immunology
Edratide (TV 4710) is a synthetic peptide of 19 amino acid based on the complementarity-determining region 1 (CDR1) of a human anti-DNA antibody that expresses a major idiotype denoted 16/6 Id. Edratide reduces the rates of apoptosis (Apoptosis) and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL. Edratide has the potential for the research of systemic lupus erythematosus (SLE) .

HY-105037A

Forigerimod TFA IPP-201101 TFA	Autophagy	Inflammation/Immunology
Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-105037

Forigerimod IPP-201101	Autophagy	Inflammation/Immunology
Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .

HY-P5509

C5aR1 antagonist peptide	Peptides	Others
C5aR1 antagonist peptide is a biological active peptide. (This linear peptide is derived from the C-terminus of the chemokine, complement fragment 5 anaphylatoxin (C5a). This peptide functions to inhibit C5a binding and function at human and rat C5a receptors. C5a is crucial to triggering cellular immune responses and its overexpression is involved in arthritis, Alzheimer’s disease, cystic fibrosis, systemic lupus erythematosus, and other immunoinflammatory diseases.)

Cat. No.	Product Name	Target	Research Area

HY-P99267

Rontalizumab RhuMab IFNalpha; Anti-Human IFN alpha Recombinant Antibody	Inhibitory Antibodies	Inflammation/Immunology
Rontalizumab is a humanized IgG1 monoclonal antibody targets IFN-α. Rontalizumab can be used for the research of systemic lupus erythematosus[1].

HY-P99842A

Dapirolizumab	TNF Receptor	Inflammation/Immunology
Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus .

HY-P99315

Ruplizumab BG 9588; Anti-Human CD40L Recombinant Antibody	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized monoclonal anti-CD40L (TNF Receptor) IgG1κ antibody. Ruplizumab has the potential for systemic lupus erythematosus disease research .

HY-P99219

Sifalimumab MEDI-545; MDX 1103	IFNAR	Inflammation/Immunology
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research .

HY-P99168

Anifrolumab 1 Publications Verification	Inhibitory Antibodies	Inflammation/Immunology
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .

HY-P99220

Tabalumab LY2127399	TNF Receptor	Inflammation/Immunology Cancer
Tabalumab (LY2127399) is a human anti-BAFF (B-cell activating factor) monoclonal antibody (IgG4 type) with neutralising activity against membrane bound and soluble BAFF. Tabalumab can be used in studies of autoimmune diseases such as rheumatoid arthritis, renal failure and systemic lupus erythematosus .

HY-P99761

Obexelimab XmAb5871	CD19 Apoptosis	Inflammation/Immunology
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .

HY-P99325

Toralizumab IDEC-131; Anti-Human CD40 ligand Recombinant Antibody	TNF Receptor	Inflammation/Immunology
Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .

HY-P9952

Belimumab 2 Publications Verification LymphoStat B	TNF Receptor CD20	Inflammation/Immunology Cancer
Belimumab (LymphoStat B) is a humanized IgG1λ monoclonal antibody against B-lymphocyte stimulator (BLyS) protein. Belimumab antagonizes BLyS activity in autoimmune diseases and B-lymphocyte malignancies. Belimumab can be used for systemic lupus erythematosus (SLE) research .

HY-P99893

Rozibafusp alfa AMG-570	Inhibitory Antibodies	Others
Rozibafusp alfa (AMG-570) is a humanized IgG2-κ monoclonal antibody targets ICOSL and BAFF. Prezalumab demonstrates beneficial activities on the arthritis of systemic lupus erythematosus. Prezalumab can be used for the research of sjogren's syndrome cutaneous lupus erythematosus, psoriasis and systemic lupus erythematosus (SLE) .

HY-P99529

Valziflocept BAX1810; TAK-752	Inhibitory Antibodies	Inflammation/Immunology
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81169A

	PD-1 Antibody(YA3401) Programmed cell death protein 1; CD279; CD279 antigen; hPD 1; hPD-1; hSLE1; PD 1; PD1; PDCD 1; PDCD1; PDCD1_HUMAN; Programmed cell death 1; Protein PD 1; Protein PD-1; SLEB2; systemic lupus erythematosus susceptibility 2.	WB, IHC-P, ICC/IF, FC	Human
	PD-1 Antibody is an unconjugated, approximately 32 kDa, rabbit-derived, anti-PD-1 monoclonal antibody. PD-1 Antibody can be used for: WB, IHC-P, Flow-Cyt, IF/ICC expriments in human background without labeling.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-150740

ODN 21595		CpG ODNs
ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE) .

HY-150740A

ODN 21595 sodium		CpG ODNs
ODN 21595 sodium is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 sodium inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 sodium reduces the expression of CD86 and HLA-DR. ODN 21595 sodium has the potential for the research of systemic lupus erythematosus (SLE) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

systemic lupus erythematosus

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Natural
Products